Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Referred to the House Committee on Energy and Commerce.

• S 735 Identical bill Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
• HR 7148 Consolidated Appropriations Act, 2026
• S 891 Bipartisan Health Care Act
• HR 1768 Lower Costs for Everyday Americans Act

• Introduced in House Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

• Energy and Commerce Committee
  House of Representatives

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

• INDIGO HILL STRATEGIES
  for SICK CELLS · Illinois · 3rd Quarter 2026 (July 1 - Sep 30)
• OGR
  for LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIP · Michigan · 3rd Quarter 2026 (July 1 - Sep 30)
• TERUMO BCT, INC.
  for TERUMO BCT, INC. · Colorado · 2nd Quarter 2026 (Apr 1 - June 30)
• THE MCMANUS GROUP
  for FULCRUM THERAPEUTICS · Massachusetts · 2nd Quarter 2026 (Apr 1 - June 30)
• INDIGO HILL STRATEGIES
  for SICK CELLS · Illinois · 2nd Quarter 2026 (Apr 1 - June 30)
• OGR
  for LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIP · Michigan · 2nd Quarter 2026 (Apr 1 - June 30)

Bodies those filers lobbied

• HOUSE OF REPRESENTATIVES
  30 filings
• SENATE
  24 filings
• Centers For Medicare and Medicaid Services (CMS)
  7 filings
• Health & Human Services, Dept of (HHS)
  6 filings
• Social Security Administration (SSA)
  3 filings
• Bureau of Industry and Security (BIS)
  2 filings
• Food & Drug Administration (FDA)
  1 filing
• Internal Revenue Service (IRS)
  1 filing

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.